Fig. 3.

Tumor burden changes during first-line pembrolizumab plus chemotherapy combination treatment. The spider plot shows the tumor burden dynamics of the 133 patients, in reference to the baseline tumor burden as 1.0. Patients whose tumor burden stayed below the baseline burden (< 1.0 or < 0% increase) had longer overall survival compared to others who had ≥ 0% increase in tumor burden in the subsequent analyses. One patient experienced pseudoprogression, with an initial tumor burden increase meeting the criteria for RECIST progression followed by subsequent tumor reduction (black line indicated by an arrow)